Nascent Biotech Balans Gezondheid
Financiële gezondheid criteriumcontroles 0/6
Nascent Biotech has a total shareholder equity of $-514.5K and total debt of $59.0K, which brings its debt-to-equity ratio to -11.5%. Its total assets and total liabilities are $227.4K and $741.9K respectively.
Belangrijke informatie
-11.5%
Verhouding schuld/eigen vermogen
US$59.00k
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$47.39k |
| Aandelen | -US$514.54k |
| Totaal verplichtingen | US$741.93k |
| Totaal activa | US$227.39k |
Recente financiële gezondheidsupdates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: NBIO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langlopende schulden: NBIO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: NBIO has negative shareholder equity, which is a more serious situation than a high debt level.
Schuld verminderen: NBIO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: NBIO has less than a year of cash runway based on its current free cash flow.
Voorspelling contante baan: NBIO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.3% each year